Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2024-04-01 | Reverse | 1:8 |
| 2019-07-25 | Reverse | 1:10 |
| 2007-11-26 | Reverse | 1:200 |
Pluri Inc. is a Haifa-based biotech company developing placenta-derived cell therapies, including PLX-PAD and PLX-R18, for inflammatory, muscle, hematologic, and radiation conditions, with several products in advanced clinical trials.

Pluri, in partnership with Miss Universe Skincare, is launching a cell-based skincare line in early 2026 using proprietary 3D cell expansion and exosome technologies to target skin rejuvenation in the growing aesthetics and wellness market.
Overall rating: C
| PEER | PRICE | |
|---|---|---|
QTTB | $15.97 | COMPARE |
SABS | $3.78 | COMPARE |
ANTX | $5.81 | COMPARE |
BOLD | $3.00 | COMPARE |
NXTC | $6.29 | COMPARE |
IBIO | $1.43 | COMPARE |
INTS | $4.86 | COMPARE |
JSPR | $0.72 | COMPARE |